Skip to main content
PMC home page
Emerging Infectious Diseases logoLink to Emerging Infectious Diseases
. 2000 Sep-Oct;6(5):458–465. doi: 10.3201/eid0605.000503

Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response.

P T Kimmitt 1, C R Harwood 1, M R Barer 1
PMCID: PMC2627954  PMID: 10998375

Abstract

Toxin synthesis by Shiga toxin-producing Escherichia coli (STEC) appears to be coregulated through induction of the integrated bacteriophage that encodes the toxin gene. Phage production is linked to induction of the bacterial SOS response, a ubiquitous response to DNA damage. SOS-inducing antimicrobial agents, particularly the quinolones, trimethoprim, and furazolidone, were shown to induce toxin gene expression in studies of their effects on a reporter STEC strain carrying a chromosome-based stx2::lacZ transcriptional fusion. At antimicrobial levels above those required to inhibit bacterial replication, these agents are potent inducers (up to 140-fold) of the transcription of type 2 Shiga toxin genes (stx2); therefore, they should be avoided in treating patients with potential or confirmed STEC infections. Other agents (20 studied) and incubation conditions produced significant but less striking effects on stx2 transcription; positive and negative influences were observed. SOS-mediated induction of toxin synthesis also provides a mechanism that could exacerbate STEC infections and increase dissemination of stx genes. These features and the use of SOS-inducing antibiotics in clinical practice and animal husbandry may account for the recent emergence of STEC disease.

Full Text

The Full Text of this article is available as a PDF (145.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acheson D. W. Nomenclature of enterotoxins. Lancet. 1998 Apr 4;351(9108):1003–1003. doi: 10.1016/s0140-6736(05)78992-3. [DOI] [PubMed] [Google Scholar]
  2. Carter A. O., Borczyk A. A., Carlson J. A., Harvey B., Hockin J. C., Karmali M. A., Krishnan C., Korn D. A., Lior H. A severe outbreak of Escherichia coli O157:H7--associated hemorrhagic colitis in a nursing home. N Engl J Med. 1987 Dec 10;317(24):1496–1500. doi: 10.1056/NEJM198712103172403. [DOI] [PubMed] [Google Scholar]
  3. Cheetham B. F., Katz M. E. A role for bacteriophages in the evolution and transfer of bacterial virulence determinants. Mol Microbiol. 1995 Oct;18(2):201–208. doi: 10.1111/j.1365-2958.1995.mmi_18020201.x. [DOI] [PubMed] [Google Scholar]
  4. Drlica K., Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377–392. doi: 10.1128/mmbr.61.3.377-392.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dundas S., Todd W. T. Clinical presentation, complications and treatment of infection with verocytotoxin-producing Escherichia coli. Challenges for the clinician. Symp Ser Soc Appl Microbiol. 2000;(29):24S–30S. doi: 10.1111/j.1365-2672.2000.tb05329.x. [DOI] [PubMed] [Google Scholar]
  6. Fuchs S., Mühldorfer I., Donohue-Rolfe A., Kerényi M., Emödy L., Alexiev R., Nenkov P., Hacker J. Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microb Pathog. 1999 Jul;27(1):13–23. doi: 10.1006/mpat.1999.0279. [DOI] [PubMed] [Google Scholar]
  7. Grif K., Dierich M. P., Karch H., Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1998 Nov;17(11):761–766. doi: 10.1007/s100960050181. [DOI] [PubMed] [Google Scholar]
  8. Karmali M. A., Petric M., Lim C., Fleming P. C., Steele B. T. Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet. 1983 Dec 3;2(8362):1299–1300. doi: 10.1016/s0140-6736(83)91167-4. [DOI] [PubMed] [Google Scholar]
  9. Kimmitt P. T., Harwood C. R., Barer M. R. Induction of type 2 Shiga toxin synthesis in Escherichia coli O157 by 4-quinolones. Lancet. 1999 May 8;353(9164):1588–1589. doi: 10.1016/s0140-6736(99)00621-2. [DOI] [PubMed] [Google Scholar]
  10. Lesesne J. B., Rothschild N., Erickson B., Korec S., Sisk R., Keller J., Arbus M., Woolley P. V., Chiazze L., Schein P. S. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989 Jun;7(6):781–789. doi: 10.1200/JCO.1989.7.6.781. [DOI] [PubMed] [Google Scholar]
  11. Lewin C. S., Amyes S. G. The role of the SOS response in bacteria exposed to zidovudine or trimethoprim. J Med Microbiol. 1991 Jun;34(6):329–332. doi: 10.1099/00222615-34-6-329. [DOI] [PubMed] [Google Scholar]
  12. Matsushiro A., Sato K., Miyamoto H., Yamamura T., Honda T. Induction of prophages of enterohemorrhagic Escherichia coli O157:H7 with norfloxacin. J Bacteriol. 1999 Apr;181(7):2257–2260. doi: 10.1128/jb.181.7.2257-2260.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mead P. S., Griffin P. M. Escherichia coli O157:H7. Lancet. 1998 Oct 10;352(9135):1207–1212. doi: 10.1016/S0140-6736(98)01267-7. [DOI] [PubMed] [Google Scholar]
  14. Mühldorfer I., Hacker J., Keusch G. T., Acheson D. W., Tschäpe H., Kane A. V., Ritter A., Olschläger T., Donohue-Rolfe A. Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect Immun. 1996 Feb;64(2):495–502. doi: 10.1128/iai.64.2.495-502.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Neely M. N., Friedman D. I. Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol Microbiol. 1998 Jun;28(6):1255–1267. doi: 10.1046/j.1365-2958.1998.00890.x. [DOI] [PubMed] [Google Scholar]
  16. Ostroff S. M., Tarr P. I., Neill M. A., Lewis J. H., Hargrett-Bean N., Kobayashi J. M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989 Dec;160(6):994–998. doi: 10.1093/infdis/160.6.994. [DOI] [PubMed] [Google Scholar]
  17. Pavia A. T., Nichols C. R., Green D. P., Tauxe R. V., Mottice S., Greene K. D., Wells J. G., Siegler R. L., Brewer E. D., Hannon D. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr. 1990 Apr;116(4):544–551. doi: 10.1016/s0022-3476(05)81600-2. [DOI] [PubMed] [Google Scholar]
  18. Plunkett G., 3rd, Rose D. J., Durfee T. J., Blattner F. R. Sequence of Shiga toxin 2 phage 933W from Escherichia coli O157:H7: Shiga toxin as a phage late-gene product. J Bacteriol. 1999 Mar;181(6):1767–1778. doi: 10.1128/jb.181.6.1767-1778.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Proulx F., Seidman E. Is antibiotic therapy of mice and humans useful in Escherichia coli O157:H7 enteritis? Eur J Clin Microbiol Infect Dis. 1999 Aug;18(8):533–534. doi: 10.1007/s100960050343. [DOI] [PubMed] [Google Scholar]
  20. Quillardet P., Hofnung M. The SOS chromotest: a review. Mutat Res. 1993 Oct;297(3):235–279. doi: 10.1016/0165-1110(93)90019-j. [DOI] [PubMed] [Google Scholar]
  21. Riley L. W., Remis R. S., Helgerson S. D., McGee H. B., Wells J. G., Davis B. R., Hebert R. J., Olcott E. S., Johnson L. M., Hargrett N. T. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983 Mar 24;308(12):681–685. doi: 10.1056/NEJM198303243081203. [DOI] [PubMed] [Google Scholar]
  22. Scotland S. M., Willshaw G. A., Smith H. R., Rowe B. Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect. 1987 Dec;99(3):613–624. doi: 10.1017/s0950268800066462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Takahashi K., Narita K., Kato Y., Sugiyama T., Koide N., Yoshida T., Yokochi T. Low-level release of Shiga-like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem. Antimicrob Agents Chemother. 1997 Oct;41(10):2295–2296. doi: 10.1128/aac.41.10.2295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wong C. S., Jelacic S., Habeeb R. L., Watkins S. L., Tarr P. I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. 2000 Jun 29;342(26):1930–1936. doi: 10.1056/NEJM200006293422601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yee A. J., De Grandis S., Gyles C. L. Mitomycin-induced synthesis of a Shiga-like toxin from enteropathogenic Escherichia coli H.I.8. Infect Immun. 1993 Oct;61(10):4510–4513. doi: 10.1128/iai.61.10.4510-4513.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yoh M., Frimpong E. K., Honda T. Effect of antimicrobial agents, especially fosfomycin, on the production and release of Vero toxin by enterohaemorrhagic Escherichia coli O157:H7. FEMS Immunol Med Microbiol. 1997 Sep;19(1):57–64. doi: 10.1111/j.1574-695X.1997.tb01072.x. [DOI] [PubMed] [Google Scholar]
  27. al-Jumaili I., Burke D. A., Scotland S. M., al-Mardini H., Record C. O. A method of enhancing verocytotoxin production by Escherichia coli. FEMS Microbiol Lett. 1992 Jun 1;72(2):121–125. doi: 10.1016/0378-1097(92)90516-q. [DOI] [PubMed] [Google Scholar]

Articles from Emerging Infectious Diseases are provided here courtesy of Centers for Disease Control and Prevention

RESOURCES